Collaborations & Alliances

Sanofi, MedImmune in RSV Alliance

MedImmune to lead development, AstraZeneca retains manufacturing activities, Sanofi-Pasteur will lead commercialization

Author Image

By: Kristin Brooks

Managing Editor, Contract Pharma

Sanofi and its vaccines business unit Sanofi Pasteur entered an agreement with MedImmune, the biologics R&D arm of AstraZeneca, to develop and commercialize monoclonal antibody MEDI8897 for the prevention of Respiratory Syncytial Virus (RSV) in infants. According to the CDC, RSV is the most common cause of lower respiratory tract infections in children younger than 1 year in the U.S. and worldwide.  MEDI8897 is a highly potent monoclonal antibody (mAb) that neutralizes RSV by binding the...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters